The global type 2 diabetes market is set to almost double from $31.2 billion in 2015 to $58.7 billion by 2025, representing a compound annual growth rate of 6.5%, according to research and consulting firm GlobalData.
The company’s latest report* states that this growth, which will occur across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, China, and India, will primarily be attributable to a dramatic increase in the diagnosis and prevalence of the disease, and the fact that the rise in type 2 diabetes-related comorbidities has fueled a more aggressive approach in treatment and the use of multiple-drug therapies.
Jesus Cuaron, Ph.D., PPM, GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders, explains: “Increases in disease incidences will result from increased life expectancy and lifestyle changes, such as dietary changes and a reduction in exercise.
“Indeed, the US will be impacted the most by such changes, increasing its global market share from 58% to 66% during the forecast period.”
Due to the increasing prevalence and progressive nature of type 2 diabetes, there are considerably high unmet needs within the indication. Overall, these unmet needs are interrelated and include improved durability of treatment, a better balance of efficacy of glycemic control with cardiovascular safety, hypoglycemia avoidance, and tolerability and ease of compliance.
Cuaron continues: “Currently, all available treatments for type 2 diabetes are initially effective and reduce complication rates. The need for drugs which are able to maintain glycemic control in the long term, however, represents a significant growth opportunity for new patent-protected products.
“Molecules in the earlier stages of development – Phase II or earlier – employ various novel mechanisms of action. Early-stage novel drug classes include those such as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors and glucokinase activators”
GlobalData believes that in order to address the biggest unmet need in type 2 diabetes, new drugs must address the problem of insulin resistance, as this is the root of the disease.
“New products must address insulin resistance while offering a strong safety profile and not causing weight gain,” the analyst concludes.
Filed Under: Drug Discovery